Improvement of motor function and neuromuscular disorders by repetitive transcranial magnetic stimulation therapy in children with cerebral palsy

Therapeutic effects of repetitive transcranial magnetic stimulation therapy on central nervous system structure and function, neuromuscular properties and gait in children with cerebral palsy

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016092525568N2

Enrollment

100

Registered

2016-11-10

Start date

2015-11-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

spastic hemiplegic cerebral palsy. Spastic hemiplegic cerebral palsy

Interventions

Intervention 1: Intervention group: will receive 25 minutes of 1 Hz repetitive transcranial magnetic stimulation (1500 pulses) with air film coil for 3 days per week for 8 weeks. The stimulation may b

Treatment - Devices

Intervention group: will receive 25 minutes of 1 Hz repetitive transcranial magnetic stimulation (1500 pulses) with air film coil for 3 days per week for 8 weeks. The stimulation may be paused based o

Control group: will receive 25 minutes of 1 Hz repetitive transcranial magnetic stimulation (1500 pulses) with sham coil for 3 days per week for 8 weeks.

Eligibility

Sex/Gender

All

Age

4 Years to 14 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: hemiplegic patients diagnosed by a pediatric neurologist; spasticity in lower extremities (Modified Ashworth Scale score more than 1); ability to attend training or test sessions; ability of following commands Exclusion criteria: having severe mental retardation; epilepsy; chromosomal anomaly; or genetic syndrome; severe brain structural anomaly; pacemaker or any other metallic implants; not attending treatment sessions regularly

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Mean Diffusivity. Timepoint: before intervention; one month after the beginning of intervention; at the end of intervention; one month after the end of intervention. Method of measurement: Magnetic Resonance Imaging Acquisition; Post Analysis.;Berg Balance Scale. Timepoint: before intervention; one month after the beginning of intervention; at the end of intervention; one month after the end of intervention. Method of measurement: Clinical evaluations.;Center of Pressure Distance. Timepoint: before intervention; one month after the beginning of intervention; at the end of intervention; one month after the end of intervention. Method of measurement: Gait Analaysis.;Stride Velocity. Timepoint: before intervention; one month after the beginning of intervention; at the end of intervention; one month after the end of intervention. Method of measurement: Gait Analaysis.;Maximum Voluntary Conraction. Timepoint: before intervention; one month after the beginning of intervention; at the end of intervention; one month after the end of intervention. Method of measurement: Isokinetic.;Fractional Anisotropy. Timepoint: before intervention; one month after the beginning of intervention; at the end of intervention; one month after the end of intervention. Method of measurement: Magnetic Resonance Imaging Acquisition; Post Analysis.;Transcranial Magnetic Stimulation Motor threshold. Timepoint: before intervention; one month after the beginning of intervention; at the end of intervention; one month after the end of intervention. Method of measurement: Transcranial Magnetic Stimulation Device; Electromyography Device.;Hoffman Reflex. Timepoint: before intervention; one month after the beginning of intervention; at the end of intervention; one month after the end of intervention. Method of measurement: Electromyography Device.;Muscle Weakness. Timepoint: before intervention; one month after the beginning of intervention; at the end of intervention; one month after the end of intervent	—

Measure

Time frame

Mean Diffusivity. Timepoint: before intervention; one month after the beginning of intervention; at the end of intervention; one month after the end of intervention. Method of measurement: Magnetic Resonance Imaging Acquisition; Post Analysis.;Berg Balance Scale. Timepoint: before intervention; one month after the beginning of intervention; at the end of intervention; one month after the end of intervention. Method of measurement: Clinical evaluations.;Center of Pressure Distance. Timepoint: before intervention; one month after the beginning of intervention; at the end of intervention; one month after the end of intervention. Method of measurement: Gait Analaysis.;Stride Velocity. Timepoint: before intervention; one month after the beginning of intervention; at the end of intervention; one month after the end of intervention. Method of measurement: Gait Analaysis.;Maximum Voluntary Conraction. Timepoint: before intervention; one month after the beginning of intervention; at the end of intervention; one month after the end of intervention. Method of measurement: Isokinetic.;Fractional Anisotropy. Timepoint: before intervention; one month after the beginning of intervention; at the end of intervention; one month after the end of intervention. Method of measurement: Magnetic Resonance Imaging Acquisition; Post Analysis.;Transcranial Magnetic Stimulation Motor threshold. Timepoint: before intervention; one month after the beginning of intervention; at the end of intervention; one month after the end of intervention. Method of measurement: Transcranial Magnetic Stimulation Device; Electromyography Device.;Hoffman Reflex. Timepoint: before intervention; one month after the beginning of intervention; at the end of intervention; one month after the end of intervention. Method of measurement: Electromyography Device.;Muscle Weakness. Timepoint: before intervention; one month after the beginning of intervention; at the end of intervention; one month after the end of intervent

—

Secondary

Measure	Time frame
-. Timepoint: -. Method of measurement: -.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactParmida Moradi Birgani

Tehran University of Medical Sciences

parmida.mb@gmail.com+98 21 6646 6383

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026